HLB Panagene to Present Artificial Nucleic Acid Research Achievements at Global Conference
HLB Panagene will showcase its artificial nucleic acid (PNA) research achievements at the 22nd Oligonucleotide Therapeutics Society (OTS 2026) to be held from October 11 to 14.
According to HLB Panagene on September 29, the study analyzes how the type and position of chemical modifications applied to PNA affect the splicing regulatory effects. Splicing is an “editing process” in which unnecessary parts are removed and only essential parts are retained in RNA before proteins are synthesized. By regulating this process, it is possible to alter the proteins produced.
HLB Panagene explained that this research demonstrates the potential to extend its accumulated PNA technology in diagnostics to the next-generation oligonucleotide therapeutics field.
In particular, this research is expected to serve as a core foundational technology for the development of AOC (antibody-oligonucleotide conjugates), which is currently under preparation. This is because the accumulated expertise in optimizing PNA sequences and chemical modifications can be applied to the design and efficacy improvement of PNA payloads conjugated to AOCs.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
An official from HLB Panagene stated, “The OTS 2026 presentation will be an opportunity to demonstrate the competitiveness of our PNA design and chemical modification technologies developed over the years, as well as to verify the potential for expansion into therapeutic applications on a global stage.” The official added, “We plan to utilize the technology and data secured through this research to drive the development of PNA-based new drugs and AOC candidates, while also actively seeking to expand our global partnerships.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.